RARA CRAFT DATABASE for FDA Medical Devices
510(k)K173683

FDA DEVICE FACTS

LIAISON BRAHMS PCT II GEN, LIAISON Control BRAHMS PCT II GEN, LIAISON BRAHMS PCT II GEN Verifiers

DiaSorin, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEFebruary 27, 2018PRODUCT CODEPRI

Indications for use

LIAISON® BRAHMS PCT® II GEN assay uses chemiluminescence immunoassay (CLIA) technology for the in vitro quantitative determination of Procalcitonin in human serum and lithium heparin plasma specimens. Used in conjunction with other laboratory findings and clinical assessments, LIAISON® BRAHMS PCT® II GEN is intended for use as follows:

- to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock,

- to aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time.

- to aid in decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) – in an inpatient setting or an emergency department, DiaSorin LIAISON® BRAHMS PCT® II GEN Premarket Notification Section 5 Page 5 - 2

- to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis.

The LIAISON® Control BRAHMS PCT® (level 1 and level 2) are intended for use as assayed quality control samples to monitor the performance and reliability of the LIAISON® BRAHMS PCT® II GEN assay. The performance characteristics of LIAISON® BRAHMS PCT ® II GEN controls have not been established with any other assay or instrument platform different from the LIAISON® Analyzer.

The LIAISON ® BRAHMS PCT® II GEN calibration verifiers (four levels) are assayed quality control materials intended in the quantitative verification of calibration and reportable range of the LIAISON ® BRAHMS PCT® II GEN assay. The performance characteristics of LIAISON ® BRAHMS PCT ® II GEN calibration verifiers have not been established in connection with any other assay or instrument platforms different from the LIAISON ® Analyzer.

KIT DESCRIPTION: The method for the quantitative determination of PCT is a sandwich chemiluminescence immunoassay. A specific monoclonal antibody is coated on the magnetic particles (solid phase); another monoclonal antibody (specific for a different epitope of the procalcitonin molecule) is linked to an isoluminol derivative (isoluminol- antibody conjugate). During the first incubation, PCT present in calibrators, samples or controls binds to the antibody conjugate. Then the solid phase is added to the reaction. A sandwich is formed only in the presence of PCT molecules that bridge both antibodies. After the second incubation, the unbound material is removed with a wash cycle. Subsequently, the starter reagents are added and a flash chemiluminescence reaction is thus induced. The light signal, and hence the amount of isoluminol -antibody conjugate, is measured by a photomultiplier as relative light units (RLU) and is indicative of PCT concentration present in calibrators, samples or controls. DiaSorin LIAISON® BRAHMS PCT® II GEN Premarket Notification Section 5 Page 5 - 3

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 28, 2026